Sex Specific Outcomes: Women after TAVI

Courtesy of Dr. Carlos Fava.

women taviThe benefits of transcatheter aortic valve implantation (TAVI) have been widely shown, but there is no evidence on sex-specific outcomes. Some studies have shown lower mortality and better evolution of the ventricular function in women, yet with more bleeding and stroke; however, it remains unclear.

 

This study included 1,019 patients of 82.5 mean age, with 17.8 EuroSCORE I and 8.3 STS score. 26% of patients presented diabetes and 30.8% kidney failure.

 

71% presented three of more high risk criteria, the most frequent being age ≥80 and fragility.

 

Aortic annulus was 21.8 mm and ejection fraction was 55%. The angiography showed no obstructive disease in 62% of patients, left main disease in 7.5% and triple vessel disease in 10.4%.

 

738 patients (72.4%) had a history of pregnancy, only 31 with associated complications.

 

17.5% had osteoporosis and one third of them had been treated. 10% was associated with frailty and osteoporosis.

 

Breast and gynecologic cancer rates were 9.3% and 2.3% respectively.

 

90.6% of procedures used the femoral access site, the preferred valve was the CoreValve (47.2%), followed by the Sapiens (41.7%). 42.1% of patients received second generation valves.

 

Results at 30 days were:

 

  • Combined safety end point VARC-2: 14%.
  • All-cause mortality: 3.4%.
  • Cardiac death: 3.3%.
  • Stroke: 1.3%.
  • Major vascular complication: 7.7%.
  • Major bleeding: 4.4%.
  • Coronary obstruction: 0.7%.
  • Need of second valve: 1.7%.
  • Conversion to surgery: 0.7%.
  • Need of definite pacemaker: 12.1%.
  • Aortic regurgitation ≥2: 1.4%.
  • Aortic regurgitation ≥3: 1.9%.

 

Event predictors were prior stroke, high STS score and <30% ejection fraction, while prior pregnancy was associated to lower events rate at 30 days.

 

Conclusion

This is the first all-female registry on TAVI with specific information about women at intermediate-high risk, at 30 days. VARC-2 final safety end point was 14% with low mortality and stroke at 30 days. Randomized studies on TAVI vs. surgery on intermediate risk patients are necessary.

 

Editorial Comment

This is the first registry with an important number of patients that show TAVI is safe for women. It looks into female specific characteristics and shows pregnancy has a protective effect. This should be analyzed in larger studies.

 

Original Title: Acute and 30-days Outcomes in Women after TAVR. Results from the WIN-TAVI (Women´s International Transcatheter Aortic Valve Implantation) Real-World Registry.

Reference: Alaide Chieffo, et al J Am Coll Cardiol interv 2016;9:1589-600

 

Courtesy of Dr. Carlos Fava. Favaloro Foundation, Buenos Aires, Argentina.

 

We value your opinion. You are more than welcome to leave your comments, thoughts, questions or suggestions here below.

More articles by this author

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...